An ounce of prevention...What are the returns: Second edition, 1999

American Journal of Preventive Medicine

Volumn 16, Issue 3, 1999, Pages 248-263

  Messonnier, Mark L ^a   Corso, Phaedra S ^a   Teutsch, Steven M ^b   Haddix, Anne C ^c   Harris, Jeffrey R ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Clinical preventive services; Cost effectiveness; Prevention

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HEALTH PROMOTION; HEALTH SERVICE; PREVENTIVE MEDICINE; QUALITY OF LIFE; WELLBEING;

EID: 0033120372     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-3797(99)00002-1     Document Type: Review

References (90)

1. Centers for Disease Control and Prevention. An Ounce of Prevention ... What are the Returns? Atlanta, Georgia: US Dept. of Health and Human Services. 1999. In press.
2. US Preventive Services Task Force. Guide to Clinical Preventive Services 2nd Ed. 1996;Williams & Wilkins, Baltimore.
3. Haddix A.C., Teutsch S.M., Shaffer P.A., Dunet D.O. Prevention effectiveness: A guide to decision analysis and economic evaluation. 1996;Oxford University Press, New York.
4. Gold M.R., Siegel J.E., Russell L.B., Weinstein M.C. Cost-effectiveness in Health and Medicine. 1996;Oxford University Press, New York.
5. Sosin D.M., Sacks J.J., Webb K.W. Pediatric head injuries and deaths from bicycling in the United States. Pediatrics. 98:1996;868-870.
6. Thompson R.S., Rivara F.P., Thompson D.C. A case-control study of the effectiveness of bicycle safety helmets. N Engl J Med. 320:1989;1361-1367.
7. Sacks J.J., Kresnow M., Houston B., Russell J. Bicycle helmet use among American children, 1994. Inj Prev. 2:1996;258-262.
8. Rodgers G.B., Tinsworth D.K., Polen C., et al. Bicycle Use and Hazard Patterns in the United States. 1994;US Consumer Product Safety Commission, Washington, DC.
9. Hatziandreu E.J., Sacks J.J., Brown R., Taylor W.R., Rosenberg M.L., Graham J.D. The cost effectiveness of three programs to increase use of bicycle helmets among children. Public Health Rep. 110:1995;251-259.
10. American Cancer Society. Cancer Facts and Figures-1997. 1997;American Cancer Society, Atlanta.
11. Brown M.L., Fintor L. Economic burden of cancer. Greenwald P., Kramer B.S., Weed D.L., Cancer Prevention and Control. 1995;M. Dekker, New York.
12. Elixhauser A. Costs of breast cancer and the cost-effectiveness of cancer screening. Int J Technol Assess Health Care. 7:1991;604-615.
13. Mushlin A.I., Fintor L. Is screening for breast cancer cost-effective? Cancer. 69:1992;1957-1962.
14. White E., Urban N., Taylor V. Mammography utilization, public health impact, and cost-effectiveness in the United States. Annu Rev Public Health. 14:1993;605-633.
15. Eddy D.M. Screening for breast cancer. Ann Intern Med. 111:1989;389-399.
16. International Agency for Research on Cancer Working Group on Evaluation of Cervical Screening Programmes. Screening for squamous cervical cancer: Duration of low risk after negative results of cervical cytology and its implications for screening policies. BMJ. 293:1986;659-664.
17. Muller C., Mandelblatt J., Schechter C., et al. Costs and Effectiveness of Cervical Cancer Screening in Elderly Women. 1990;Office of Technology Assessment, US Congress, Washington, DC.
18. Eddy D.M. Screening for cervical cancer. Ann Intern Med. 113:1990;214-226.
19. CDC. Update: Blood lead levels - United States, 1991-1994. [published erratum appears in MMWR 1997; 46:607] MMWR. 46:1997;141-146.
20. Pirkle J.L., Brody D.J., Gunter E.W., et al. The decline in blood lead levels in the United States the National Health and Nutrition Examination Surveys (NHANES). JAMA. 272:1994;284-291.
21. Weitz S., Clickner R.P., Blackburn A., Buches D. Comprehensive and Workable Plan for the Abatement of Lead-based Paint in Privately Owned Housing: Report to Congress. 1990;US Department of Housing and Urban Development, Washington, DC.
22. CDC. Strategic Plan for the Elimination of Childhood Lead Poisoning. Atlanta: US Department of Health and Human Resources, Public Health Service, CDC, 1991:10-12,1-25 (Appendix II).
23. CDC. Summary of notifiable diseases, United States, 1993. MMWR. 42:1994;1-73.
24. CDC. Notice to readers: Final 1994 reports of notifiable diseases. MMWR. 44:1995;537-543.
25. CDC. Progress toward elimination of Haemophilus influenzae type B disease among infants and children - United States, 1987-1993. MMWR. 43:1994;144-148.
26. CDC. Progress toward elimination of Haemophilus influenza type B disease among infants and children - United States, 1993-1994. MMWR. 44:1995;545-550.
27. Hatziandreu E.J., Brown R.E., Halpern M.T. A Cost Benefit Analysis of the Measles-mumps-rubella (MMR) Vaccine. 1994;Battelle, Arlington, VA.
28. Hatziandreu E.J., Palmer C.S., Brown R.E., Halpern M.T. A Cost Benefit Analysis of the Diphtheria-tetanus-pertussis Vaccine. 1994;Battelle, Arlington, VA.
29. Lieu T.A., Cochi S.L., Black S.B., et al. Cost effectiveness of a routine varicella vaccination program for US children. JAMA. 271:1994;375-381.
30. CDC. Recommendations for the prevention and management of Chlamydia trachomatis infections, 1993. MMWR. 42:(No. RR-12):1993;1-39.
31. Washington A.E., Johnson R.E., Sanders L.L. Jr. Chlamydia trachomatis infections in the United States: what are they costing us? JAMA. 257:1987;2070-2072.
32. Haddix A.C., Hillis S.D., Kassler W.J. The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women. Sex Transm Dis. 22:1995;274-280.
33. Scholes D., Stergachis A., Heidrich F.E., Andrilla H., Holmes K.K., Stamm W.E. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med. 334:1996;1362-1366.
34. Marrazzo J.M., Celum C.L., Hillis S.D., Fine D., DeLisle S., Handsfield H.H. Performance and cost-effectiveness of selective screening criteria for Chlamydia trachomatis infection in women. Sex Transm Dis. 24:1997;131-141.
35. American Cancer Society. Cancer Facts and Figures-1998. 1998;American Cancer Society, Atlanta.
36. Wagner J.L., Herdman R.C., Wadhwa S. Cost effectiveness of colorectal cancer screening in the elderly. Ann Intern Med. 115:1991;807-817.
37. American Heart Association. 1997 Heart and Stroke Statistical Update. 1997;American Heart Association, Dallas.
38. CDC. Public health focus physical activity and the prevention of coronary heart disease. MMWR. 42:1993;669-672.
39. Hatziandreu E.I., Koplan J.P., Weinstein M.C., Caspersen C.J., Warner K.E. A cost-effectiveness analysis of exercise as a health promotion activity. Am J Public Health. 78:1988;1417-1421.
40. Oster G., Thompson D. Estimated effects of reducing dietary saturated fat intake on the incidence and costs of coronary heart disease in the United States. J Am Diet Assoc. 96:1996;127-131.
41. CDC. Fluoridation Census 1992. 1993;US Department of Health and Human Services, Public Health Service, CDC, Atlanta.
42. CDC. Public health focus: Fluoridation of community water systems. MMWR 1992; 41:372-5, 381.
43. Will J.C., Geiss L.S., Wetterhall S.F. Diabetic retinopathy. [Letter] N Engl J Med. 323:1990;613.
44. Javitt J.C., Aiello L.P. Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med. 124:1996;164-169.
45. Karon J.M., Rosenberg P.S., McQuillan G., Khare M., Gwinn M., Peterson L.R. Prevalence of HIV infection in the United States, 1984 to 1992. JAMA. 276:1996;126-131.
46. Singh GK, Kochanek KD, MacDorman MF. Advance Report of Final Mortality Statistics, 1994. Hyattsville, MD: US Department of Health and Human Resources, Public Health Service, CDC, 1996. (Monthly vital statistics report, vol 45[suppl]:1-80).
47. CDC. Update: Mortality attributable to HIV infection among persons aged 25-44 years - United States, 1994. MMWR. 45:1996;121-125.
48. CDC. HIV/AIDS Surveillance Report. 9:1997;1-43 US Department of Health and Human Resources, Public Health Service, CDC, Atlanta.
49. Hellinger F.J. The lifetime cost of treating a person with HIV. JAMA. 270:1993;474-478.
50. Hellinger F.J. Forecasts of the costs of medical care for persons with HIV: 1992-1995. Inquiry. 29:1992;356-365.
51. McCarthy B.D., Wong J.B., Munoz A., Sonnenberg F.A. Who should be screened for HIV infection? A cost-effectiveness analysis. Arch Intern Med. 153:1993;1107-1116.
52. Holtgrave D.R., Valdiserri R.O., Gerber A.R., Hinman A.R. Human immunodeficiency virus counseling, testing, referral, and partner notification services: A cost-benefit analysis. Arch Intern Med. 153:1993;1225-1230.
53. Gorsky R.D., Farnham P.G., Straus W.L., et al. Preventing perinatal transmission of HIV - Costs and effectiveness of a recommended intervention. Public Health Rep. 111:1996;335-341.
54. CDC. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 44:1995;1-22.
55. Nichol K.L., Margolis K.L., Wuorenma J., Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med. 331:1994;778-784.
56. CDC. Final results Medicare influenza vaccine demonstration - Selected states, 1988-1992. MMWR. 42:1993;601-604.
57. CDC. From Data to Action: CDC's Public Health Surveillance for Women, Infants, and Children. 1995;US Department of Health and Human Services. Public Health Service, CDC, Atlanta.
58. Paneth N.S. The problem of low birth weight. Future Child. 5:1995;19-34.
59. Gorsky R.D., Colby J.P. The cost effectiveness of prenatal care in reducing low birth weight in New Hampshire. Health Serv Res. 24:1989;583-598.
60. Lewit E.M., Baker L.S., Corman H., Shiono P.H. The direct cost of low birth weight. Future Child. 5:1995;35-56.
61. Buescher P.A., Larson L.C., Nelson M.D., Lenihan A.J. Prenatal WIC participation can reduce low birth weight and newborn medical costs: A cost-benefit analysis of WIC participation in North Carolina. J Am Diet Assoc. 93:1993;163-166.
62. Cragan JD, Roberts HE, Edmonds LD, et al. Surveillance for anencephaly and spina bifida and the impact of prenatal diagnosis - United States, 1985-1994. In: CDC Surveillance Summaries (August 25). MMWR 1995; 44(No. SS-4):1-13.
63. CDC. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR. 41:1992;1-6.
64. Kelly A.E., Haddix A.C., Scanlon K.S., Helmick C.G., Mulinare J. Worked example: Cost-effectiveness of strategies to prevent neural tube defects. Gold M.R., Siegel J.E., Russell L.B., et al. Cost Effectiveness in Health and Medicine. 1996;313-348 Oxford University Press, New York.
65. Margolis H.S., Coleman P.J., Brown R.E., Mast E.E., Sheingold S.H., Arevalo J.A. Prevention of hepatitis B virus transmission by immunization: An economic analysis of current recommendations. JAMA. 274:1995;1201-1208.
66. CDC. Update: Pneumococcal polysaccaride vaccine usage, United States. MMWR 1984; 33:273-6, 281.
67. Williams W.W., Hickson M.A., Kane M.A., Kendal A.P., Spika J.S., Hinman A.R. Immunization policies and vaccine coverage among adults: The risk for missed opportunities. Ann Intern Med. 108:1988;616-625.
68. Butler J.C., Breiman R.F., Campbell J.F., Lipman H.B., Broome C.V., Facklam R.R. Pneumococcal polysaccharide vaccine efficacy: An evaluation of current recommendations. JAMA. 270:1993;1826-1831.
69. Shapiro E.D., Clemens J.D. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med. 101:1984;325-330.
70. Sisk J.E., Riegelman R.K. Cost effectiveness of vaccination against pneumococcal pneumonia: An update. Ann Intern Med. 104:1986;79-86.
71. Gable C.B., Holzer S.S., Engelhart L., et al. Pneumococcal vaccine: Efficacy and associated cost savings. JAMA. 264:1990;2910-2915.
72. Scott R.B., Castro O. Screening for sickle cell hemoglobinopathies. JAMA. 241:1979;1145-1147.
73. Motulsky A.G. Frequency of sickling disorders in US blacks. N Engl J Med. 288:1973;31-33.
74. Agency for Health Care Policy and Research. Sickle Cell Anemia: Screening, Diagnosis, Management, and Counseling in Newborns and Infants. Rockville, MD: US Department of Health and Human Resources, Public Health Service, AHCPR, 1993. (Clinical practice guideline no. 6; publication no. 93-0562).
75. Tsevat J., Wong J.B., Pauker S.G., Steinberg M.H. Neonatal screening for sickle cell disease: A cost-effectiveness analysis. J Pediatr. 118:1991;546-554.
76. Gessner B.D., Teutsch S.M., Shaffer P.A. A cost-effectiveness evaluation of newborn hemoglobinopathy screening from the perspective of state health care systems. Early Hum Dev. 45:1996;257-275.
77. CDC. Cigarette smoking-attributable mortality and years of potential life lost - United States, 1990. MMWR. 42:1993;645-649.
78. CDC. Medical-care expenditures attributable to cigarette smoking - United States, 1993. MMWR. 43:1994;469-472.
79. CDC. Trends in smoking initiation among adolescents and young adults - United States, 1980-1989. MMWR. 44:1995;521-525.
80. Hodgson T.A. Cigarette smoking and lifetime medical expenditures. Milbank Q. 70:1992;81-125.
81. Cummings S.R., Rubin S.M., Oster G. The cost-effectiveness of counseling smokers to quit. JAMA. 261:1989;75-79.
82. CDC. Reported Tuberculosis in the United States, 1997. 1998;US Department of Health and Human Services, CDC, Washington, DC.
83. CDC. Screening for tuberculosis and tuberculosis infection in high-risk populations: Recommendations of the Advisory Council for the elimination of tuberculosis. MMWR. 44:(No. RR-11):1995;19-34.
84. Thompson N.J. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT trial. Bull World Health Organ. 60:1982;555-564.
85. Shulkin D.J., Brennan P.J. The cost of caring for patients with tuberculosis: Planning for a disease on the rise. Am J Infect Control. 23:1995;1-4.
86. Brown R.E., Miller B., Taylor W.R., et al. Health-care expenditures for tuberculosis in the United States. Arch Intern Med. 155:1995;1595-1600.
87. Snider D.E., Caras G.J., Koplan J.P. Preventive therapy with isoniazid: Cost-effectiveness of different durations of therapy. JAMA. 255:1986;1579-1583.
88. Mohle-Boetani J.C., Miller B., Halpern M., et al. School-based screening for tuberculosis infection: A cost-benefit analysis. JAMA. 274:1995;613-619.
89. Arrow K.J., Cropper M.L., Eads G.C., et al. Is there a role for benefit-cost analysis in environmental, health, and safety regulation? Science. 272:1996;221-222.
90. Sassone P.G., Schaffer W.A. Cost-benefit analysis: A handbook. 1978;Academic Press, New York.